TapImmune, Inc. Announces $2 Million Registered Direct Offering

Business Wire

SEATTLE--(BUSINESS WIRE)--

TapImmune, Inc. (the “Company”), (TPIV), today announced that it has entered into a definitive agreement with an institutional investor for a registered direct placement of $2,000,000 of common stock at a price of $1.06 per share.

In addition, the Company will issue to the investor warrants to purchase up to 1,886,793 shares of common stock. The warrants have an exercise price of $1.17 per share and are exercisable for five years following issuance.

The offering is expected to close on or about August 14, 2014, subject to satisfaction of customary closing conditions.

H.C. Wainwright & Co., LLC, acted as the exclusive placement agent in connection with this offering.

The securities described above are being offered pursuant to a shelf registration statement (File No. 333-196115), which was declared effective by the United States Securities and Exchange Commission (“SEC”) on Jul 23, 2014. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. When filed with the SEC, copies of the prospectus supplement and the accompanying base prospectus relating to this offering may be obtained at the SEC's website at http://www.sec.gov or by request from H.C. Wainwright & Co., LLC by emailing placements@hcwco.com.

About TapImmune Inc.

TapImmune Inc. is an immunotherapy company specializing in the development of innovative vaccine technologies for the treatment of cancer and infectious disease. The Company’s vaccine compositions, peptide or nucleic acid-based, comprise one or multiple naturally processed epitopes (NPEs) designed to comprehensively stimulate a patients’ killer T-cells, helper T-cells and to restore or further augment antigen presentation by using proprietary nucleic acid-based expression systems. The Company’s vaccine compositions may be used as stand-alone medications or in combination with current treatment modalities. Please visit the Company’s website at www.tapimmune.com for details.

Safe Harbor Statement

This press release contains certain statements that may include “forward-looking statements.” All statements other than statements of historical fact included herein are “forward-looking statements.” These forward-looking statements are often identified by the use of forward-looking terminology such as “believes,” “expects” or similar expressions, involving known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including the risk factors discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on the SEC's website (http://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these risk factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

Contact:
TapImmune, Inc.
Glynn Wilson, Ph.D., 866-359-7541
Chairman & CEO
View Comments (0)